Loading...
Images of Dr. Reimar Schlingensiepen
(0 from 0 )1
0
0
News
BIOPARK8 Brain-Network startet in der BioRegio Regensburg, BioPark...
www.pressebox.de
BioPark Regensburg GmbH, Mit einem neuen Expertennetzwerk fördert der BioPark in Regensburg Gründer, Unternehmen und Öffentlichkeit in Sachen Leb...
AudioCure Pharma schließt Finanzierungsrunde über neun ...
www.goingpublic.de
Dr. Reimar Schlingensiepen, COO, ist ebenfalls Arzt, Gründer mehrerer Unternehmen und Manager biopharmazeutischer Unternehmen.
AudioCure Pharma GmbH nomina il Dott. Reimar Schlingensiepen al ruolo...
www.informazione.it
Il Dott. Reimar Schlingensiepen succede al Prof. Hans Rommelspacher, il fondatore di AudioCure, in qualità di CEO Il…
AudioCure Pharma GmbH beruft Dr. Reimar Schlingensiepen ...www.pharma-zeitung.de › ... › AudioCure Pharma GmbH
www.pharma-zeitung.de
Dr. Reimar Schlingensiepen (left), the newly appointed CEO of AudioCure Pharma GmbH, takes over from Prof. Hans Rommelspacher, founder ...
Network Profiles
LinkedIn: Reimar Schlingensiepen - Deutschland | LinkedIn
Übersicht von Reimar Schlingensiepen Aktuell CEO bei Themeos Interim Management and Consulting Früher COO, CFO bei Antisense Pharma GmbH Head Marketing and Product
LinkedIn: Reimar Schlingensiepen | LinkedIn
Reimar Schlingensiepens berufliches Profil anzeigen LinkedIn ist das weltweit größte professionelle Netzwerk, das Fach- und Führungskräften wie Reimar ...
Reimar Schlingensiepen AudioCure Pharma GmbH [LSG]...
www.life-sciences-germany.com
Life Sciences Business Intelligence for Germany, Austria and Switzerland
Interests
AudioCure Pharma's AC102 receives EMA orphan drug ...
www.tmcnet.com
Dr. Reimar Schlingensiepen, CEO of AudioCure commented: "The orphan drug designation is a major milestone in the development program of AC102, enabling a more efficient and cost-effective regulatory pathway, and is therefore an important step in pursuing our goal of developing treatments for hearing disorders with significant unmet medical needs.
AudioCure Pharma’s AC102 receives EMA orphan drug designation for the...
markets.financialcontent.com
FinancialContent fully hosted finance channel
AudioCure Pharma GmbH nombra CEO al Dr. Reimar ...
www.businesswire.com
El Dr. Reimar Schlingensiepen sustituye al Prof. Hans Rommelspacher, fundador de AudioCure, como CEO; Prof. Rommelspacher continuará ...
Reimar Schlingensiepen - Patents
www.freshpatents.com
Recent bibliographic sampling of Reimar Schlingensiepen patents listed/published in the public domain by the USPTO (USPTO Patent Application #,Title): ...
Business Profiles
Xing: Dr. Reimar Schlingensiepen
Dr. / CEO / Regensburg / Biotechnologie, Strategieberatung, High-Tech, Pharmazeutische Industrie, Interim Management, Coaching, Projektmanagement / , GRI Bio Inc
patentbuddy: Reimar Schlingensiepen
BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH, Regensburg, DE
Reimar Schlingensiepen AudioCure Pharma GmbH [LSE] Life ...
www.life-sciences-europe.com
"Press Release: Dr. Reimar Schlingensiepen Has Joined AudioCure". We are fortunate to announce that Dr. Reimar Schlingensiepen has joined AudioCure as the new COO. Dr. Schlingensiepen is an experienced serial entrepreneur and manager for biotech, medtech and diagnostics companies.
Just a moment...
www.zoominfo.com
View Reimar Schlingensiepen's business profile as Chief Executive Officer at JADO Technologies GmbH and see work history, affiliations and more.
Employees
Management | Audiocure
www.audiocure.com
Management “The strength of AudioCure lies in the fine balance between profound science and outside-the-box thinking. With it´s unique development approach AudioCure could revolutionize the market of pharmacotherapy in otology and hearing devices one day.” ... Dr. Reimar Schlingensiepen, MD Chief Executive Officer. Dr. Schlingensiepen has ...
News, Nachrichten und Meldungen über Antisense Pharma
www.bionity.com
Tagesaktuelle und branchenrelevante Nachrichten, News und Meldungen über Antisense Pharma für Biotechnologie, Life Sciences, Pharma, Diagnostik, Medizin finden...
Property
MX/a OLIGONUCLEOTIDE-, PROTEIN AND/OR ...
patentscope.wipo.int
IPC: A61K Applicants: ANTISENSE PHARMA GMBH.*. Inventors: KARL-HERMANN SCHLINGENSIEPEN REIMAR SCHLINGENSIEPEN ANDREAS ...
Books & Literature
Antisense Oligonucleotides: From Technology to Therapy...
fr.eurobuch.ch
Trouvez tous les livres de Reimar Schlingensiepen, R. Schlingensiepen, W. Brysch - Antisense Oligonucleotides: From Technology to Therapy (Ex Libris Roche) ...
Transforming Growth Factor-β in Cancer Therapy, Volume II | E-kirja |...
www.ellibs.com
Ellibs E-kirjakauppa - E-kirja: Transforming Growth Factor-β in Cancer Therapy, Volume II - Tekijä: Jakowlew, Sonia B. - Hinta: 167,34€
Transforming Growth Factor-β in Cancer Therapy, Volume II | Ebook |...
www.ellibs.com
Ellibs Ebookstore - Ebook: Transforming Growth Factor-β in Cancer Therapy, Volume II - Author: Jakowlew, Sonia B. - Price: 167,34€
Transforming Growth Factor-Beta in Cancer Therapy, Volume II: Cancer...
books.google.de
... The Netherlands Karl-Hermann Schlingensiepen, MD, PhD ' Antisense Pharma GmbH, Regensburg, Germany Reimar Schlingensiepen, MD, PhD ' Antisense ...
Related Documents
Die MIG Fonds Substanz entscheidet!. Portfolio- und Fondsmanagement...
docslide.de
Folie 1 Die MIG Fonds Substanz entscheidet! Folie 2 Portfolio- und Fondsmanagement Auswahl, Verhandlung und Betreuung der Zielunternehmen Due-Diligence Prüfung...
Scientific Publications
Cytokine & Growth Factor Reviews | TGF-ß | ScienceDirect.com
www.sciencedirect.com
Original Research Article; Pages ; Karl-Hermann Schlingensiepen, Reimar Schlingensiepen, Andreas Steinbrecher, Peter Hau, Ulrich Bogdahn, Birgit ...
Publications
Inhibition of TGF-beta2 with AP in recurrent malignant gliomas:...
core.ac.uk
Inhibition of TGF-beta2 with AP in recurrent malignant gliomas: from preclinical to phase I/II studies . By Peter Hau, Piotr Jachimczak, Reimar Schlingensiepen ...
Publications Authored by Reimar Schlingensiepen | PubFacts
www.pubfacts.com
Publications Authored by Reimar Schlingensiepen
Changes of synapsin I messenger RNA expression during rat brain...
link.springer.com
Synapsin I is a synaptic phosphoprotein that is involved in the short-term regulation of neurotransmitter release. In this report we present the first...
Publications Authored by Piotr Jachimczak | PubFacts
www.pubfacts.com
Publications Authored by Piotr Jachimczak
Reports & Statements
AudioCure Blog Dr. Reimar Schlingensiepen Owler Reports
www.owler.com
We are fortunate to announce that Dr. Reimar Schlingensiepen has joined AudioCure as the new COO. Dr. Schlingensiepen is an experienced ...
Antisense-Studie, Regensburg - Hirntumor Forum Neuroonkologie
forum.hirntumorhilfe.de
Hirntumor Forum : Antisense-Studie, Regensburg
TGF-ß2 wirksam oder wirkungslos - Hirntumor Forum Neuroonkologie
forum.hirntumorhilfe.de
Hirntumor Forum : TGF-ß2 wirksam oder wirkungslos
Miscellaneous
Reimar Schlingensiepen | LinkedIn
www.linkedin.com
View Reimar Schlingensiepen’s professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Reimar Schlingensiepen ...
Reimar Schlingensiepen | Professional Profile - LinkedIn
www.linkedin.com
View Reimar Schlingensiepen's profile on LinkedIn, the world's largest professional community. Reimar has 13 jobs listed on their profile. See the complete ...
WO A3 - A method for reversing the ...
patents.google.com
Reimar Schlingensiepen Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date
EP B1 - Antisense-oligonucleotides for the treatment of...
patents.google.com
... Georg-Ferdinand Schlingensiepen, Karl-Hermann Schlingensiepen, Reimar Schlingensiepen: Aanvrager: BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH
Die MIG Fonds Substanz entscheidet!. - ppt herunterladen
slideplayer.org
... Stefan Müllner Chemiker, mehr als 18 Jahre Erfahrung in F&E, Mitgründer der Protagen AG Dr. Reimar Schlingensiepen Onkologe, Mitgründer von Antisense ...
WO A3 - Melange comprenant un inhibiteur ou un suppresseur...
patents.google.com
Le mélange décrit comprend au moins un inhibiteur ou suppresseur de l'expression d'un gène et au moins une molécule qui se lie au produit d'expression de...
CA A1 - Antisense oligonucleotides for inhibiting the formation...
patents.google.com
Inventors, Karl-Hermann Schlingensiepen, Reimar Schlingensiepen, Piotr Jachimczak, Gerhard Stauder, Astrid Bischof, Michael Hafner, Tamara Egger.
AudioCure Pharma's AC102 receives EMA orphan drug ...
finance.yahoo.com
Dr. Reimar Schlingensiepen, CEO of AudioCure commented: “The orphan drug designation is a major milestone in the development program ...
Dr. Reimar Schlingensiepen has joined AudioCure | Audiocure
www.audiocure.de
We are happy to announce that Dr. Reimar Schlingensiepen has joined AudioCure as COO. Dr. Schlingensiepen is an experienced ...
EP A2 - A method for reversing the immunosuppressive effects of...
patents.google.com
Inventors, Rainer Apfel, Ulrich Bogdahn, Wolfgang Brysch, Piotr Jachimczak, Karl -Hermann Schlingensiepen, Reimar Schlingensiepen.
US A1 - Mixture comprising an inhibitor or suppresor of a...
patents.google.com
A mixture comprising at least one inhibitor or suppressor of the expression of a gene and at least one molecule binding to an expression product of said...
AudioCure appoints Dr. Reimar Schlingensiepen as …
www.audiocure.com
· Reimar Schlingensiepen succeeds Prof. Hans Rommelspacher, the founder of AudioCure, as CEO. Rommelspacher will continue as CSO. AudioCure recently secured funding of about 9 million euros in a Series A financing round from Austrian MED-EL Elektromedizinische Geräte GmbH, German investor High-Tech Gruenderfonds and private investors.
CA C - Oligonucleotide-prolyethylene glycol compound
patents.google.com
A conjugate or compound comprising polyethyleneglycol and an oligonucleotide, wherein at least one polyethyleneglycol is linked to the 5´-end of the...
DE D1 - ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG...
patents.google.com
Uitvinders, Wolfgang Brysch, Karl-Hermann Schlingensiepen, Reimar Schlingensiepen, Georg-F Schlingensiepen. Aanvrager, Biognostik Ges.
Dr. Reimar Schlingensiepen | chemanager-online.com - Chemie und Life...
www.chemanager-online.com
Dr. Reimar Schlingensiepen News & Opinions AudioCure Pharma schließt Finanzierungsrunde erfolgreich ab AudioCure, ein pharmazeutisches...
WO A3 - ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF...
patents.google.com
Inventors, Ulrich Bogdahn, Wolfgang Brysch, Georg-Ferdinan Schlingensiepen, Karl-Hermann Schlingensiepen, Reimar Schlingensiepen.
WO A3 - An antisense oligonucleotide to inhibit melanoma...
patents.google.com
... Karl-Hermann Schlingensiepen, Reimar Schlingensiepen. Requerente, Antisense Pharma Gmbh, Karl-Hermann Schlingensiepen, Reimar Schlingensiepen.
WO A2 - Use of low doses of oligonucleotides antisense to...
patents.google.com
This invention is related to the use of at least one oligonucleotide with a length of from about 8 to about 30 nucleotide building blocks for manufacturing a...
CA A1 - A method for reversing the Google
patents.google.com
Other languages: English: French; Inventor: Karl-Hermann Schlingensiepen: Reimar Schlingensiepen: Rainer Apfel: Wolfgang Brysch: Piotr Jachimczak: Ulrich ...
CA C - Procede servant a stimuler le systeme immunitaire...
patents.google.com
Other languages: English; Inventor: Karl-Hermann Schlingensiepen: Reimar Schlingensiepen: Wolfgang Brysch; Current Assignee. The listed assignees may be ...
Related search requests for Dr. Reimar Schlingensiepen
| Wolfgang Brysch Ulrich Bogdahn Piotr Jachimczak | Hans Rommelspacher Wolfgang Götz Ralf Wagner | Rainer Apfel Stefan Müllner Karl-Hermann Schlingensiepen |
People Forename "Reimar" (64) Name "Schlingensiepen" (12) |
sorted by relevance / date